I don't know where it will close today but I hope you are right. My guess for the next few weeks is that the price will continue to drop, probably below $6.00/share. It will eventually recover tremendously when and if the trial is resumed. Also, they still have other products/applications in their pipeline and their profit potential remains strong, but investors will have to be a bit more patient now before they will see any payback. Many of us have been in this stock for the long haul anyway, and this type of setback (hopefully temporary in this case) is common in biotechs.